Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains

Tianyu Zhang, William Ramses Bishai, Jacques H. Grosset, Eric Nuermberger

Research output: Contribution to journalArticle

Abstract

Mycobacterium ulcerans causes Buruli ulcer, an emerging infectious disease for which antimicrobial therapy has only recently proven to be beneficial. The discovery and development of new drugs against M. ulcerans are severely impeded by its very slow growth. Recombinant bioluminescent strains have proven useful in drug development for other mycobacterial infections, but the ability of such strains to discriminate bacteriostatic from bactericidal activity has not been well demonstrated. We engineered recombinant M. ulcerans strains to express luxAB from Vibrio harveyi. In drug susceptibility tests employing a wide range of antimicrobial agents and concentrations, the relative light unit (RLU) count measured in real time was a reliable surrogate marker for CFU counts available 3 months later, indicating utility for the rapid determination of drug susceptibility and discrimination of bacteriostatic and bactericidal effects. A second important finding of this study is that the addition of subinhibitory concentrations of the ATP-binding cassette transporter inhibitor reserpine increases the susceptibility of M. ulcerans to tetracycline and erythromycin, indicating that drug efflux may explain at least part of the intrinsic resistance of M. ulcerans to these agents.

Original languageEnglish (US)
Pages (from-to)2806-2813
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume54
Issue number7
DOIs
StatePublished - 2010

Fingerprint

Mycobacterium ulcerans
Pharmaceutical Preparations
Buruli Ulcer
Emerging Communicable Diseases
Vibrio
ATP-Binding Cassette Transporters
Reserpine
Erythromycin
Anti-Infective Agents
Tetracycline
Biomarkers
Light
Growth
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases
  • Medicine(all)

Cite this

Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. / Zhang, Tianyu; Bishai, William Ramses; Grosset, Jacques H.; Nuermberger, Eric.

In: Antimicrobial Agents and Chemotherapy, Vol. 54, No. 7, 2010, p. 2806-2813.

Research output: Contribution to journalArticle

@article{59d14dbd61b242868147aeb98f00fd1e,
title = "Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains",
abstract = "Mycobacterium ulcerans causes Buruli ulcer, an emerging infectious disease for which antimicrobial therapy has only recently proven to be beneficial. The discovery and development of new drugs against M. ulcerans are severely impeded by its very slow growth. Recombinant bioluminescent strains have proven useful in drug development for other mycobacterial infections, but the ability of such strains to discriminate bacteriostatic from bactericidal activity has not been well demonstrated. We engineered recombinant M. ulcerans strains to express luxAB from Vibrio harveyi. In drug susceptibility tests employing a wide range of antimicrobial agents and concentrations, the relative light unit (RLU) count measured in real time was a reliable surrogate marker for CFU counts available 3 months later, indicating utility for the rapid determination of drug susceptibility and discrimination of bacteriostatic and bactericidal effects. A second important finding of this study is that the addition of subinhibitory concentrations of the ATP-binding cassette transporter inhibitor reserpine increases the susceptibility of M. ulcerans to tetracycline and erythromycin, indicating that drug efflux may explain at least part of the intrinsic resistance of M. ulcerans to these agents.",
author = "Tianyu Zhang and Bishai, {William Ramses} and Grosset, {Jacques H.} and Eric Nuermberger",
year = "2010",
doi = "10.1128/AAC.00400-10",
language = "English (US)",
volume = "54",
pages = "2806--2813",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains

AU - Zhang, Tianyu

AU - Bishai, William Ramses

AU - Grosset, Jacques H.

AU - Nuermberger, Eric

PY - 2010

Y1 - 2010

N2 - Mycobacterium ulcerans causes Buruli ulcer, an emerging infectious disease for which antimicrobial therapy has only recently proven to be beneficial. The discovery and development of new drugs against M. ulcerans are severely impeded by its very slow growth. Recombinant bioluminescent strains have proven useful in drug development for other mycobacterial infections, but the ability of such strains to discriminate bacteriostatic from bactericidal activity has not been well demonstrated. We engineered recombinant M. ulcerans strains to express luxAB from Vibrio harveyi. In drug susceptibility tests employing a wide range of antimicrobial agents and concentrations, the relative light unit (RLU) count measured in real time was a reliable surrogate marker for CFU counts available 3 months later, indicating utility for the rapid determination of drug susceptibility and discrimination of bacteriostatic and bactericidal effects. A second important finding of this study is that the addition of subinhibitory concentrations of the ATP-binding cassette transporter inhibitor reserpine increases the susceptibility of M. ulcerans to tetracycline and erythromycin, indicating that drug efflux may explain at least part of the intrinsic resistance of M. ulcerans to these agents.

AB - Mycobacterium ulcerans causes Buruli ulcer, an emerging infectious disease for which antimicrobial therapy has only recently proven to be beneficial. The discovery and development of new drugs against M. ulcerans are severely impeded by its very slow growth. Recombinant bioluminescent strains have proven useful in drug development for other mycobacterial infections, but the ability of such strains to discriminate bacteriostatic from bactericidal activity has not been well demonstrated. We engineered recombinant M. ulcerans strains to express luxAB from Vibrio harveyi. In drug susceptibility tests employing a wide range of antimicrobial agents and concentrations, the relative light unit (RLU) count measured in real time was a reliable surrogate marker for CFU counts available 3 months later, indicating utility for the rapid determination of drug susceptibility and discrimination of bacteriostatic and bactericidal effects. A second important finding of this study is that the addition of subinhibitory concentrations of the ATP-binding cassette transporter inhibitor reserpine increases the susceptibility of M. ulcerans to tetracycline and erythromycin, indicating that drug efflux may explain at least part of the intrinsic resistance of M. ulcerans to these agents.

UR - http://www.scopus.com/inward/record.url?scp=77953775139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953775139&partnerID=8YFLogxK

U2 - 10.1128/AAC.00400-10

DO - 10.1128/AAC.00400-10

M3 - Article

C2 - 20421401

AN - SCOPUS:77953775139

VL - 54

SP - 2806

EP - 2813

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

ER -